Traumatic brain injury

Current Opinion in Critical Care

Volumn 15, Issue 6, 2009, Pages 548-553

  Aarabi, Bizhan ^a   Simard, J Marc ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Blast TBI; Decompressive craniectomy; IMPACT; Neuroprotection; PTSD; TBI; Trials

Indexed keywords

CITICOLINE; CYCLOSPORIN A; GLIBENCLAMIDE; MANNITOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROGESTERONE; PROPOFOL; TRANEXAMIC ACID; VASOPRESSIN;

BLOOD CLOTTING DISORDER; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN PERFUSION; CRANIECTOMY; DECOMPRESSION SURGERY; DISEASE SEVERITY; HEAD INJURY; HEMODYNAMICS; HEMORRHAGIC SHOCK; HUMAN; INTRACRANIAL HYPERTENSION; NEUROPROTECTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS; STROKE; SURGICAL TECHNIQUE; TRAUMATIC BRAIN INJURY;

BLAST INJURIES; BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; DECOMPRESSIVE CRANIECTOMY; HUMANS; INTERNATIONALITY; STRESS DISORDERS, POST-TRAUMATIC;

EID: 74949142887     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32833190da     Document Type: Review

References (76)

1. Beauchamp K, Mutlak H, Smith WR, et al. Pharmacology of traumatic brain injury: where is the 'golden bullet'? Mol Med 2008; 14:731-740.
2. Ling G, Bandak F, Armonda R, et al. Explosive blast neurotrauma. J Neurotrauma 2009; 26:815-825.
3. Brain Trauma Foundation New York. Guidelines for management of severe head injury. J Neurotrauma 2007; 24 Suppl:S-1-S-106.
4. MRC CRASH Trial Collaborators. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008; 336:425-429.
5. Hoge CW, McGurk D, Thomas JL, et al. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med 2008; 358:453-463.
6. Schneiderman AI, Braver ER, Kang HK. Understanding sequelae of injury mechanisms and mild traumatic brain injury incurred during the conflicts in Iraq and Afghanistan: persistent postconcussive symptoms and posttraumatic stress disorder. Am J Epidemiol 2008; 167:1446-1452.
7. Margulies S, Hicks R, and Combination Therapies for Traumatic Brain Injury Workshop Leaders. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma 2009; 26:925-939.
8. Maas AI, Lingsma HF, and IMPACT Study Group. New approaches to increase statistical power in TBI trials: insights from the IMPACT study. Acta Neurochir Suppl 2008; 101:119-124.
9. Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24:329-337. (Pubitemid 46492154)
10. Saatman KE, Duhaime AC, Bullock R, et al., and Workshop Scientific Team and Advisory Panel Members. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008; 25:719-738.
11. Povlishock JT, Katz DI. Update of neuropathology and neurological recovery after traumatic brain injury. J Head Trauma Rehabil 2005; 20:76-94.
12. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007; 99:4-9.
13. Xiong Y, Mahmood A, Chopp M. Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs 2009; 14:67-84.
14. Stoica B, Byrnes K, Faden AI. Multifunctional drug treatment in neurotrauma. Neurotherapeutics 2009; 6:14-27.
15. Vink R, Nimmo AJ. Multifunctional drugs for head injury. Neurotherapeutics 2009; 6:28-42.
16. Simard JM, Kilbourne M, Tsymbalyuk O, et al. Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage following brain contusion. J Neurotrauma 2009. [Epub ahead of print]
17. Tzortzopoulou A, Cepeda MS, Schumann R, Carr DB. Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database Syst Rev 2008:CD006883.
18. Trabold R, Krieg S, Schöller K, Plesnila N. Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice. J Neurotrauma 2008; 25:1459-1465.
19. Poole NA, Agrawal N. Cholinomimetic agents and neurocognitive impairment following head injury: a systematic review. Brain Inj 2008; 22:519-534.
20. Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis 2008; 5:167-177.
21. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2008; 131 (Pt 2):318-328.
22. Hu Z, Li Y, Fang M, et al. Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration. Curr Med Chem 2009; 16:1418-1425.
23. Pan DS, Liu WG, Yang XF, Cao F. Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury. Biomed Environ Sci 2007; 20:432-438.
24. Stein DG, Wright DW, Kellermann AL. Does progesterone have neuroprotective properties? Ann Emerg Med 2008; 51:164-172.
25. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007; 49:391-402.
26. Xiao G, Wei J, Yan W, et al. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12:R61.
27. Gilmer LK, Roberts KN, Scheff SW. Efficacy of progesterone following a moderate unilateral cortical contusion injury. J Neurotrauma 2008; 25:593-602.
28. De Nicola AF, Labombarda F, Deniselle MC, et al. Progesterone neuroprotection in traumatic CNS injury and motoneuron degeneration. Front Neuroendocrinol 2009; 30:173-187.
29. Schumacher M, Guennoun R, Stein DG, De Nicola AF. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther 2007; 116:77-106.
30. Sirén AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009; 6:108-127.
31. Xiong Y, Chopp M, Lee CP. Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury. Neurol Res 2009; 31:496-502.
32. Mattzeo AT, Beat A, Singh A, Bullock RM. The role of mitochondrial transition pore, and its modulation, in traumatic brain injury and delayed neurodegeneration after TBI. Exp Neurol 2009; 218:363-370.
33. Hatton J, Rosbolt B, Empey P, et al. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg 2008; 109:699-707.
34. Simard JM, Woo SK, Bhatta S, Gerzanich V. Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr Opin Pharmacol 2008; 8:42-49.
35. Simard JM, Chen M. Regulation by sulfanylurea receptor type 1 of a nonselective cation channel involved in cytotoxic edema of reactive astrocytes. J Neurosurg Anesthesiol 2004; 16:98-99.
36. Simard JM, Geng Z, Woo SK, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2009; 29:317-330.
37. Simard JM, Yurovsky V, Tsymbalyuk N, et al. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009; 40:604-609.
38. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 38:2526-2530.
39. Ling GS, Marshall SA. Management of traumatic brain injury in the intensive care unit. Neurol Clin 2008; 26:409-426.
40. Cernak I, Savic J, Ignjatovic D, Jevtic M. Blast injury from explosive munitions. J Trauma 1999; 47:96-103.
41. Charters AC 3rd, Charters AC. Wounding mechanism of very high velocity projectiles. J Trauma 1976; 16:464-470.
42. Cernak I. Preclinical models of blast TBI. Proceedings of the 26th annual national neurotrauma symposium, July 27-30, 19, 27; 2008.
43. Huang M, Theilmann RJ, Robb A, et al. Integrated imaging approach with MEG and DTI to detect mild traumatic brain injury in military and civilian patients. J Neurotrauma 2009. [Epub ahead of print]
44. Bell RS, Vo AH, Neal CJ, et al. Military traumatic brain and spinal column injury: a 5 year study of the impact blast and other military grade weaponry on the central nervous system. J Trauma 2009; 66 (4 Suppl):S104-S111.
45. Armonda RA, Bell RS, Vo AH, et al. Wartime traumatic cerebral vasospasm: recent review of combat casualties. Neurosurgery 2006; 59:1215-1225.
46. Farin A, Marshall LF. Lessons from epidemiologic studies in clinical trials of traumatic brain injury. Acta Neurochir Suppl 2004; 89:101-107.
47. Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J Neurotrauma 2009; 19:503-557.
48. Schouten JW. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature. Curr Opin Crit Care 2007; 13:134-142.
49. Clifton GL, Drever P, Valadka A, et al. Multicenter trial of early hypothermia in severe brain injury. J Neurotrauma 2009; 26:393-397.
50. Corwin HL, Gettinger A, Fabian TC, et al., and EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357:965-976.
51. Corwin HL, Gettinger A, Pearl RG, et al., and EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. J Am Med Assoc 2003; 288:2884-2886.
52. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006. update. Methods Find Exp Clin Pharmacol 2006; 28 (Suppl B):1-56.
53. Empey PE, McNamara PJ, Young B, et al. Cyclosporin A disposition following acute traumatic brain injury. J Neurotrauma 2006; 23:109-116.
54. Chen SF, Hung TH, Chen CC, et al. Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sci 2007; 81:288-298.
55. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol 6:29-38.
56. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001; 344:556-563.
57. Hutchison JS, Ward RE, Lacroix J, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med 2008; 358:2447-2456.
58. Langham J, Goldfrad C, Teasdale G, et al. Calcium channel blockers for acute traumatic brain injury. Cochrane Database Syst Rev 2003:CD000565.
59. Maas AI, Murray G, Henney H 3rd, et al., and Pharmos TBI investigators. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006; 5:38-45.
60. Marmarou A, Nichols J, Burgess J, et al. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multicenter, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J Neurotrauma 1999; 16:431-444.
61. Morris GF, Bullock R, Marshall SB, et al. Failure of the competitive N-methyl- D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J Neurosurg 1999; 91:737-743.
62. Roberts I, Yates D, Sandercock P, et al., and CRASH trial collaborators. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebocontrolled trial. Lancet 2004; 364:1321-1328.
63. Yurkewicz L, Weaver J, Bullock MR, Marshall LF. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma 2005; 22:1428-1443.
64. Maas AI, Marmarou A, Murray GD, et al. Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. J Neurotrauma 2007; 24:232-238. (Pubitemid 46492144)
65. Marmarou A, Anderson RL, Ward JD, et al. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. J Neurosurg 1991; 75:S59.
66. Miller JD. ICP monitoring: current status and future directions. Acta Neurochir [Suppl] (Wien) 1987; 85:80-86.
67. Narayan RK, Kishore PR, Becker DP, et al. Intracranial pressure: to monitor or not to monitor? A review of our experience with severe head injury. J Neurosurg 1982; 56:650-659.
68. Aarabi B, Hesdorffer DC, Ahn ES, et al. Outcome following decompressive craniectomy for malignant swelling due to severe head injury. J Neurosurg 2006; 104:469-479.
69. Eisenberg HM, Frankowski RF, Contant CF, et al. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg 1988; 69:15-23.
70. Hase U, Reulen HJ, Meinig G, Schurmann K. The influence of the decompressive operation on the intracranial pressure and the pressure-volume relation in patients with severe head injuries. Acta Neurochir (Wien) 1978; 45:1-13.
71. Heppner P, Ellegala DB, Durieux M, et al. Contrast ultrasonographic assessment of cerebral perfusion in patients undergoing decompressive craniectomy for traumatic brain injury. J Neurosurg 2006; 104:738-745.
72. Ho CL, Wang CM, Lee KK, et al. Cerebral oxygenation, vascular reactivity, and neurochemistry following decompressive craniectomy for severe traumatic brain injury. J Neurosurg 2008; 108:943-949.
73. Timofeev I, Kirkpatrick PJ, Corteen E, et al. Decompressive craniectomy in traumatic brain injury: outcome following protocol-driven therapy. Acta Neurochir Suppl 2006; 96:11-16.
74. Aarabi B, Hesdorffer DC, Simard JM, et al. Comparative study of decompressive craniectomy following mass lesion evacuation in severe head injury. Neurosurgery 2009; 64:927-940.
75. Cooper DJ, Rosenfeld JV, Murray L, et al. Early decompressive craniectomy for patients with severe traumatic brain injury and refractory intracranial hypertension: a pilot randomized trial. J Crit Care 2008; 23:387-393.
76. Hutchinson PJ, Corteen E, Czosnyka M, et al. Decompressive craniectomy in traumatic brain injury: the randomized multicenter RESCUEicp study (www.RESCUEicp.com). Acta Neurochir Suppl 2009; 96:17-20.